RxDoctor Payments Data

Mark Smith, MD

Internal Medicine · Akron, OHNPI 1497727242

Payments from drug & device makers

$925in general payments, 2019–2025

Across 79 payments — averaging $11.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$201
  • Pfizer$172
  • Amarin Pharma, Inc.$164
  • AstraZeneca$140
  • GSK$63
  • Johnson & Johnson$45
  • plus $139 from 7 others

What the payments were for

  • Food & beverage$81989%
  • Education$10611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$925 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$286,186
Medicare patients
601
Services billed
3,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,811$699,197
Invega SustennaPaliperidone Palmitate103$362,362
IngrezzaValbenazine Tosylate34$131,039
XareltoRivaroxaban319$106,890
MyrbetriqMirabegron266$100,772
JardianceEmpagliflozin251$90,443
TrulicityDulaglutide101$90,225
CreonLipase/Protease/Amylase82$77,648
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$67,607
XifaxanRifaximin42$66,004
EntrestoSacubitril/Valsartan140$52,938
NuplazidPimavanserin Tartrate21$52,263
FarxigaDapagliflozin Propanediol127$46,010
JanuviaSitagliptin Phosphate150$43,270
VraylarCariprazine Hcl59$42,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$172$724,6581,892 claims
Johnson & JohnsonInvega Sustenna, Xarelto$45$469,252422 claims
Neurocrine Biosciences, Inc.Ingrezza$11$131,03934 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$63$123,248207 claims
Astellas Pharma US IncMyrbetriq$201$100,772266 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$25$66,00442 claims
AstraZenecaFarxiga$140$46,010127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →